1.

Content of lunchboxes of Dutch primary school children and their perceptions of alternative healthy school lunch concepts

2.

Content of lunchboxes of Dutch primary school children and their perceptions of alternative healthy school lunch concepts

1.

Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) – parent form for children aged 2–18 years

2.

Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) – parent form for children aged 2–18 years

1.

T.R.H. The Dutchess of York & Princess Elizabeth with nurse.

2.

T.R.H. The Dutchess of York & Princess Elizabeth with nurse.

1.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

2.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

3.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

4.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

5.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

6.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

7.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

8.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

9.

Evolution of methylisothiazolinone sensitization: A Belgian multicentric study from 2014 to 2019.

1.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

2.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

3.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

4.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

5.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

6.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

7.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

8.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

9.

Off-label drug use in paediatric haemato-oncology patients: financial implications and proposed solutions for Belgian patients.

1.

Die Förderung der prosozialen Entwicklung durch Erzählen und Besprechen von Geschichten. Eine prozessorienterte Studie ; The enhancement of the prosocial development (of children)...

2.

Die Förderung der prosozialen Entwicklung durch Erzählen und Besprechen von Geschichten. Eine prozessorienterte Studie ; The enhancement of the prosocial development (of children)...

3.

Die Förderung der prosozialen Entwicklung durch Erzählen und Besprechen von Geschichten. Eine prozessorienterte Studie ; The enhancement of the prosocial development (of children)...

4.

Die Förderung der prosozialen Entwicklung durch Erzählen und Besprechen von Geschichten. Eine prozessorienterte Studie ; The enhancement of the prosocial development (of children)...

5.

Die Förderung der prosozialen Entwicklung durch Erzählen und Besprechen von Geschichten. Eine prozessorienterte Studie ; The enhancement of the prosocial development (of children)...

1.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

2.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

3.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

4.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

5.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

6.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

7.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

8.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

9.

Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.

1.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

2.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

3.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

4.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

5.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

6.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

7.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

8.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

9.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

1.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

2.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

3.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

4.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

5.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

6.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

7.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

8.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

9.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

1.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

2.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

3.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

4.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

5.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

6.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

7.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

8.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

9.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.